Incyte/$INCY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Incyte
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Ticker
$INCY
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
2,617
Website
Incyte Metrics
BasicAdvanced
$14B
726.51
$0.10
0.90
-
Price and volume
Market cap
$14B
Beta
0.9
52-week high
$82.15
52-week low
$53.56
Average daily volume
1.7M
Financial strength
Current ratio
2.039
Quick ratio
1.747
Long term debt to equity
0.89
Total debt to equity
1.012
Interest coverage (TTM)
83.55%
Profitability
EBITDA (TTM)
303.279
Gross margin (TTM)
37.80%
Net profit margin (TTM)
0.48%
Operating margin (TTM)
4.67%
Effective tax rate (TTM)
93.24%
Revenue per employee (TTM)
$1,690,000
Management effectiveness
Return on assets (TTM)
2.00%
Return on equity (TTM)
0.47%
Valuation
Price to earnings (TTM)
726.514
Price to revenue (TTM)
3.185
Price to book
3.72
Price to tangible book (TTM)
4.01
Price to free cash flow (TTM)
48.672
Free cash flow yield (TTM)
2.05%
Free cash flow per share (TTM)
144.83%
Growth
Revenue change (TTM)
17.13%
Earnings per share change (TTM)
-97.06%
3-year revenue growth (CAGR)
12.32%
10-year revenue growth (CAGR)
22.48%
3-year earnings per share growth (CAGR)
-71.51%
10-year earnings per share growth (CAGR)
-6.91%
What the Analysts think about Incyte
Analyst ratings (Buy, Hold, Sell) for Incyte stock.
Bulls say / Bears say
Incyte's acquisition of Escient Pharmaceuticals for $750 million enhances its pipeline with promising small-molecule drugs for immune and neuro-immune disorders, potentially driving future growth. (seekingalpha.com)
The FDA's approval of Monjuvi (tafasitamab-cxix) in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma expands Incyte's oncology portfolio, offering new revenue streams. (businesswire.com)
The appointment of Bill Meury as CEO, with his extensive experience in biopharma acquisitions, signals a strategic shift towards potential mergers and acquisitions, which could bolster Incyte's market position. (seekingalpha.com)
Incyte's stock declined by 29.6% year-to-date as of October 2023, primarily due to pipeline setbacks and increased competition for its lead drug, Jakafi. (nasdaq.com)
The FDA's approval of GSK's Ojjaara, a once-daily oral JAK1/JAK2 inhibitor for myelofibrosis, introduces significant competition to Incyte's Jakafi, potentially impacting its market share. (nasdaq.com)
Incyte's fourth-quarter earnings fell short of expectations, with full-year guidance indicating a significant deceleration in growth for key products like Jakafi and Opzelura, raising concerns about future profitability. (financialcontent.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Incyte Financial Performance
Revenues and expenses
Incyte Earnings Performance
Company profitability
Incyte News
AllArticlesVideos
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
Business Wire·22 hours ago
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·3 weeks ago
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Incyte stock?
Incyte (INCY) has a market cap of $14B as of July 25, 2025.
What is the P/E ratio for Incyte stock?
The price to earnings (P/E) ratio for Incyte (INCY) stock is 726.51 as of July 25, 2025.
Does Incyte stock pay dividends?
No, Incyte (INCY) stock does not pay dividends to its shareholders as of July 25, 2025.
When is the next Incyte dividend payment date?
Incyte (INCY) stock does not pay dividends to its shareholders.
What is the beta indicator for Incyte?
Incyte (INCY) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.